Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized single-blind trial of HD-NE02 sustained-release eye drops for dry eye disease
CTR20251824Phase 2Active
- Sponsor
- Nanjing Hengdao Pharmaceutical Technology
- Start
- May 2025
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of cyclosporine in dry eye syndrome (DED), sponsored by Nanjing Hengdao Pharmaceutical Technology. Started May 2025; status: active.
02
Drugs
cyclosporine
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on CTR20251824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251824.